Myelodysplastic syndrome following treatment of malignant melanoma with vincristine, ACNU, and dacarbazine.
Therapy-related myelodysplastic syndrome is a rare adverse effect in melanoma patients elicited by chemotherapy. We report a case of myelodysplastic syndrome following treatment of malignant melanoma with alkylating agents. Peripheral blood showed a remarkable suppression of three cell lineages, and the bone marrow was slightly hypercellular. However, no morphological abnormalities were detected in the peripheral blood or the bone marrow, and chromosomal analysis was normal.
Kageshita
T
T
Department of Dermatology, Kumamoto University, Japan.
Kuribayashi
N
N
Ono
T
T
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D001853:Bone Marrow / Q000473:pathology; D003606:Dacarbazine / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007958:Leukocyte Count; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000473:pathology; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000139:chemically induced* / Q000175:diagnosis; D015376:Nimustine / Q000008:administration & dosage / Q000627:therapeutic use; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology; D014750:Vincristine / Q000008:administration & dosage / Q000627:therapeutic use
D015376:Nimustine; D014750:Vincristine; D003606:Dacarbazine